Cargando…
The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting
Culprits of cancer development, metastasis, and drug resistance, cancer stem cells (CSCs) are characterized by specific markers, active developmental signaling pathways, metabolic plasticity, increased motility, invasiveness, and epithelial-mesenchymal transition. In breast cancer, these cells are o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807694/ https://www.ncbi.nlm.nih.gov/pubmed/35127497 http://dx.doi.org/10.3389/fonc.2021.791696 |
_version_ | 1784643739120041984 |
---|---|
author | Walker, Olivia L. Dahn, Margaret L. Power Coombs, Melanie R. Marcato, Paola |
author_facet | Walker, Olivia L. Dahn, Margaret L. Power Coombs, Melanie R. Marcato, Paola |
author_sort | Walker, Olivia L. |
collection | PubMed |
description | Culprits of cancer development, metastasis, and drug resistance, cancer stem cells (CSCs) are characterized by specific markers, active developmental signaling pathways, metabolic plasticity, increased motility, invasiveness, and epithelial-mesenchymal transition. In breast cancer, these cells are often more prominent in aggressive disease, are amplified in drug-resistant tumors, and contribute to recurrence. For breast cancer, two distinct CSC populations exist and are typically defined by CD44+/CD24- cell surface marker expression or increased aldehyde dehydrogenase (ALDH) activity. These CSC populations share many of the same properties but also exhibit signaling pathways that are more active in CD44+/CD24- or ALDH+ populations. Understanding these CSC populations and their shared or specific signaling pathways may lead to the development of novel therapeutic strategies that will improve breast cancer patient outcomes. Herein, we review the current evidence and assess published patient tumor datasets of sorted breast CSC populations for evidence of heightened prostaglandin E2 (PGE(2)) signaling and activity in these breast CSC populations. PGE(2) is a biologically active lipid mediator and in cancer PGE(2) promotes tumor progression and poor patient prognosis. Overall, the data suggests that PGE(2) signaling is important in propagating breast CSCs by enhancing inherent tumor-initiating capacities. Development of anti-PGE(2) signaling therapeutics may be beneficial in inhibiting tumor growth and limiting breast CSC populations. |
format | Online Article Text |
id | pubmed-8807694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88076942022-02-03 The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting Walker, Olivia L. Dahn, Margaret L. Power Coombs, Melanie R. Marcato, Paola Front Oncol Oncology Culprits of cancer development, metastasis, and drug resistance, cancer stem cells (CSCs) are characterized by specific markers, active developmental signaling pathways, metabolic plasticity, increased motility, invasiveness, and epithelial-mesenchymal transition. In breast cancer, these cells are often more prominent in aggressive disease, are amplified in drug-resistant tumors, and contribute to recurrence. For breast cancer, two distinct CSC populations exist and are typically defined by CD44+/CD24- cell surface marker expression or increased aldehyde dehydrogenase (ALDH) activity. These CSC populations share many of the same properties but also exhibit signaling pathways that are more active in CD44+/CD24- or ALDH+ populations. Understanding these CSC populations and their shared or specific signaling pathways may lead to the development of novel therapeutic strategies that will improve breast cancer patient outcomes. Herein, we review the current evidence and assess published patient tumor datasets of sorted breast CSC populations for evidence of heightened prostaglandin E2 (PGE(2)) signaling and activity in these breast CSC populations. PGE(2) is a biologically active lipid mediator and in cancer PGE(2) promotes tumor progression and poor patient prognosis. Overall, the data suggests that PGE(2) signaling is important in propagating breast CSCs by enhancing inherent tumor-initiating capacities. Development of anti-PGE(2) signaling therapeutics may be beneficial in inhibiting tumor growth and limiting breast CSC populations. Frontiers Media S.A. 2022-01-19 /pmc/articles/PMC8807694/ /pubmed/35127497 http://dx.doi.org/10.3389/fonc.2021.791696 Text en Copyright © 2022 Walker, Dahn, Power Coombs and Marcato https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Walker, Olivia L. Dahn, Margaret L. Power Coombs, Melanie R. Marcato, Paola The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
title | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
title_full | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
title_fullStr | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
title_full_unstemmed | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
title_short | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
title_sort | prostaglandin e2 pathway and breast cancer stem cells: evidence of increased signaling and potential targeting |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807694/ https://www.ncbi.nlm.nih.gov/pubmed/35127497 http://dx.doi.org/10.3389/fonc.2021.791696 |
work_keys_str_mv | AT walkerolivial theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT dahnmargaretl theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT powercoombsmelanier theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT marcatopaola theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT walkerolivial prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT dahnmargaretl prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT powercoombsmelanier prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT marcatopaola prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting |